Ornithine Transcarbamylase Deficiency Treatment Market
Ornithine Transcarbamylase Deficiency Treatment Market By Product (Buphenyl, Ravicti, Ammonul, Dietary Supplements), By Route of Administration (Oral, Intravenous), By Distribution Channel, By Region - Global Market Forecast 2020-2030
Analysis of Ornithine Transcarbamylase Deficiency Treatment market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary : Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market 4. Market Overview 4.1. Introduction 4.1.1. Product Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, 2018–2030 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Disease Prevalence & Incidence Rate globally with key countries 5.2. Pipeline Analysis 5.3. Standard Guidelines for Approval of Drugs 5.4. Overview of Diagnostics approach for OTC Deficiency 5.5. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact) 6. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Product 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030 6.3.1. Buphenyl 6.3.2. Ravicti 6.3.3. Ammonul 6.3.4. Dietary Supplements 6.3.5. Others 6.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product 7. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Route of Administration 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030 7.3.1. Oral 7.3.2. Intravenous 7.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration 8. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Distribution Channel 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Online Pharmacies 8.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel 9. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Region 9.1. Key Findings 9.2. Market Value Forecast, by Region 9.2.1. North America 9.2.2. Europe 9.2.3. Asia Pacific 9.2.4. Latin America 9.2.5. Middle East & Africa 9.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Region 10. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030 10.2.1. Buphenyl 10.2.2. Ravicti 10.2.3. Ammonul 10.2.4. Dietary Supplements 10.2.5. Others 10.3. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030 10.3.1. Oral 10.3.2. Intravenous 10.4. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030 10.4.1. Hospital Pharmacies 10.4.2. Retail Pharmacies 10.4.3. Online Pharmacies 10.5. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country, 2018–2030 10.5.1. U.S. 10.5.2. Canada 10.6. Market Attractiveness Analysis 10.6.1. By Product 10.6.2. By Route of Administration 10.6.3. By Distribution Channel 10.6.4. By Country 11. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030 11.2.1. Buphenyl 11.2.2. Ravicti 11.2.3. Ammonul 11.2.4. Dietary Supplements 11.2.5. Others 11.3. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030 11.3.1. Oral 11.3.2. Intravenous 11.4. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030 11.4.1. Hospital Pharmacies 11.4.2. Retail Pharmacies 11.4.3. Online Pharmacies 11.5. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030 11.5.1. Germany 11.5.2. U.K. 11.5.3. France 11.5.4. Spain 11.5.5. Italy 11.5.6. Rest of Europe 11.6. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis 11.6.1. By Product 11.6.2. By Route of Administration 11.6.3. By Distribution Channel 11.6.4. By Country/Sub-region 12. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030 12.2.1. Buphenyl 12.2.2. Ravicti 12.2.3. Ammonul 12.2.4. Dietary Supplements 12.2.5. Others 12.3. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030 12.3.1. Oral 12.3.2. Intravenous 12.4. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030 12.4.1. Hospital Pharmacies 12.4.2. Retail Pharmacies 12.4.3. Online Pharmacies 12.5. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030 12.5.1. China 12.5.2. Japan 12.5.3. India 12.5.4. Australia & New Zealand 12.5.5. Rest of Asia Pacific 12.6. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis 12.6.1. By Product 12.6.2. By Route of Administration 12.6.3. By Distribution Channel 12.6.4. By Country/Sub-region 13. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030 13.2.1. Buphenyl 13.2.2. Ravicti 13.2.3. Ammonul 13.2.4. Dietary Supplements 13.2.5. Others 13.3. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030 13.3.1. Oral 13.3.2. Intravenous 13.4. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030 13.4.1. Hospital Pharmacies 13.4.2. Retail Pharmacies 13.4.3. Online Pharmacies 13.5. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030 13.5.1. Brazil 13.5.2. Mexico 13.5.3. Rest of Latin America 13.6. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis 13.6.1. By Product 13.6.2. By Route of Administration 13.6.3. By Distribution Channel 13.6.4. By Country/Sub-region 14. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030 14.2.1. Buphenyl 14.2.2. Ravicti 14.2.3. Ammonul 14.2.4. Dietary Supplements 14.2.5. Others 14.3. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030 14.3.1. Oral 14.3.2. Intravenous 14.4. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030 14.4.1. Hospital Pharmacies 14.4.2. Retail Pharmacies 14.4.3. Online Pharmacies 14.5. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030 14.5.1. GCC Countries 14.5.2. South Africa 14.5.3. Rest of Middle East & Africa 14.6. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis 14.6.1. By Product 14.6.2. By Route of Administration 14.6.3. By Distribution Channel 14.6.4. By Country/Sub-region 15. Competition Landscape 15.1. Market Player – Competition Matrix (By Tier and Size of companies) 15.2. Market Share/Position Analysis, by Company (2019) 15.3. Company Profiles 15.3.1. Abbott 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.1.2. Company Financials 15.3.1.3. Growth Strategies 15.3.1.4. SWOT Analysis 15.3.2. Nutricia (Danone Group) 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2.2. Company Financials 15.3.2.3. Growth Strategies 15.3.2.4. SWOT Analysis 15.3.3. Mead Johnson (Reckitt Benckiser) 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.3.2. Company Financials 15.3.3.3. Growth Strategies 15.3.3.4. SWOT Analysis 15.3.4. Horizon Therapeutics plc 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.4.2. Company Financials 15.3.4.3. Growth Strategies 15.3.4.4. SWOT Analysis 15.3.5. Nestlé 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.5.2. Company Financials 15.3.5.3. Growth Strategies 15.3.5.4. SWOT Analysis 15.3.6. Bausch Health Companies, Inc. 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.6.2. Company Financials 15.3.6.3. Growth Strategies 15.3.6.4. SWOT Analysis 15.3.7. Ultragenyx Pharmaceutical Inc. 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.7.2. Company Financials 15.3.7.3. Growth Strategies 15.3.7.4. SWOT Analysis 15.3.8. Arcturus Therapeutics, Inc. 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.8.2. Company Financials 15.3.8.3. Growth Strategies 15.3.8.4. SWOT Analysis 15.3.9. Acer Therapeutics 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.9.2. Company Financials 15.3.9.3. Growth Strategies 15.3.9.4. SWOT Analysis
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
List of Tables:
Table 01: Pipeline Analysis
Table 02: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 03: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 04: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 05: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 06: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 07: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 08: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 09: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 10: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 11: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 12: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 13: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 14: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 15: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 16: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 17: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 18: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 19: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 20: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 21: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 22: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 23: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 24: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 25: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
List of Figures:
Figure 01: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, 2018–2030
Figure 02: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share, by Product, 2019
Figure 03: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share, by Route of Administration, 2019
Figure 04: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share, by Distribution Channel, 2019
Figure 05: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share, by Region, 2019
Figure 06: Regulatory Approval Process - U.S.
Figure 07: Regulatory Approval Process - Europe
Figure 08: Regulatory Approval Process - Japan
Figure 09: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share Analysis, by Product, 2019 and 2030
Figure 10: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Buphenyl, 2018–2030
Figure 11: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Ravicti, 2018–2030
Figure 12: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Ammonul, 2018–2030
Figure 13: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Dietary Supplements, 2018–2030
Figure 14: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Others, 2018–2030
Figure 15: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis, by Product, 2020–2030
Figure 16: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 17: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Oral, 2018–2030
Figure 18: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Intravenous, 2018–2030
Figure 19: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 20: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 21: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2018-2030
Figure 22: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2018-2030
Figure 23: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Online Pharmacies, 2018–2030
Figure 24: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 25: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share Analysis, by Region, 2019 and 2030
Figure 26: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis, by Region, 2020–2030
Figure 27: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 28: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country, 2019 and 2030
Figure 29: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country, 2020–2030
Figure 30: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030
Figure 31: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030
Figure 32: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 33: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 34: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 35: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 36: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 37: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 38: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 39: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030
Figure 40: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030
Figure 41: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 42: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 43: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 44: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 45: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 46: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 47: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 48: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030
Figure 49: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030
Figure 50: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 51: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 52: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 53: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 54: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 55: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 56: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 57: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030
Figure 58: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030
Figure 59: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 60: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 61: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 62: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 63: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 64: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 65: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 66: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030
Figure 67: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030
Figure 68: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 69: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 70: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 71: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 72: Market Position Analysis, 2019, by Tier and Size of Company
Figure 73: Abbott, Nutritional Business Segment - Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 74: Abbott, Nutritional Business Segment - Breakdown of Net Sales (%), by Region/Country, 2019
Figure 75: Abbott, Breakdown of Net Sales (%), by Nutritional Business Segment, 2019
Figure 76: Abbott, R&D Expenses (US$ Mn) Y-o-Y Growth (%), 2016–2019
Figure 77: Danone - Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 78: Danone - Breakdown of Net Sales (%), by Region/Country, 2019
Figure 79: Danone - Breakdown of Net Sales (%), by Business Segment, 2019
Figure 80: Reckitt Benckiser - Revenue (US$ Mn), 2016–2018
Figure 81: Reckitt Benckiser - Breakdown of Net Sales (%), by Region/Country, 2018
Figure 82: Reckitt Benckiser - Breakdown of Net Sales (%), by Business Segment, 2018
Figure 83: Horizon Therapeutics plc - Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 84: Horizon Therapeutics plc - Breakdown of Net Sales (%), by Region/County, 2019
Figure 85: Horizon Therapeutics plc - Breakdown of Net Sales (%), by Business Segment, 2019
Figure 86: RAVICTI & BUPHENYL - Product Revenue (US$ Mn), 2017–2019
Figure 87: Nestlé - Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Figure 88: Nestlé - Breakdown of Net Sales (%), by Region/County, 2019
Figure 89: Nestlé - Breakdown of Net Sales (%), by Product Line, 2019
Figure 90: Bausch Health Companies, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Figure 91: Bausch Health Companies, Inc., Breakdown of Net Sales (%), by Region/County, 2019
Figure 92: Bausch Health Companies, Inc., Breakdown of Net Sales (%), by Business Segment, 2019
Figure 93: Bausch Health Companies, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 94: Ultragenyx Pharmaceutical, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 95: Ultragenyx Pharmaceutical, Inc., Breakdown of Net Sales (%), by Region/County, 2019
Figure 96: Ultragenyx Pharmaceutical, Inc., DTX301 - R&D Expenses (US$ Mn) Y-o-Y Growth (%), 2018–2019
Figure 97: Ultragenyx Pharmaceutical, Inc., R&D Expenses (US$ Mn) Y-o-Y Growth (%), 2016–2019
Figure 98: Arcturus Therapeutics, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Figure 99: Arcturus Therapeutics, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request